Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Sarcoma 4Hypoxia 4Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Melanoma 2Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × TH 302 × Clear all
NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡